PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).

Abstract Patients with small-cell lung cancer (SCLC) patients demonstrate varied survival outcomes. Previous studies have reported that lipoproteins are associated with prognosis in various cancers; however, the role of low-density lipoprotein (LDL) and low-density lipoprotein- cholesterol (LDLR) in patients with SCLC has not been studied.
PMID
Related Publications

Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers.

High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.

Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer.

Is there any potential clinical impact of serum phosphorus and magnesium in patients with lung cancer at first diagnosis? A multi-institutional study.

Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer.

Authors

Mayor MeshTerms
Keywords

Low-density lipoprotein

Low-density lipoprotein receptor

Prognosis

Small-cell lung cancer

Journal Title bmc cancer
Publication Year Start




PMID- 28410578
OWN - NLM
STAT- MEDLINE
DA  - 20170415
DCOM- 20170418
LR  - 20170418
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 14
TI  - Serum low-density lipoprotein and low-density lipoprotein expression level at
      diagnosis are favorable prognostic factors in patients with small-cell lung
      cancer (SCLC).
PG  - 269
LID - 10.1186/s12885-017-3239-z [doi]
AB  - BACKGROUND: Patients with small-cell lung cancer (SCLC) patients demonstrate
      varied survival outcomes. Previous studies have reported that lipoproteins are
      associated with prognosis in various cancers; however, the role of low-density
      lipoprotein (LDL) and low-density lipoprotein- cholesterol (LDLR) in patients
      with SCLC has not been studied. METHODS: In this study, the impact of LDL and
      LDLR on the prognosis of SCLC patients was evaluated. A total of 601 patients
      with SCLC were retrospectively evaluated, in which 198 patients had adequate
      tissues for immunohistochemistry, and serum LDL and LDLR expression levels at
      baseline were tested. X-tile tool, and univariate and multivariate Cox analysis
      were used to assess the association between LDL, LDLR and overall survival (OS). 
      RESULTS: Univariate analysis demonstrated that a lower LDL level was
      significantly associated with superior OS (P = 0.037). Similarly, LDLR also
      significantly predicted OS (P = 0.003). Multivariate Cox analyses confirmed that 
      lower LDL and LDLR expression was independent prognostic factors associated with 
      longer OS (P = 0.019 and P = 0.027, respectively). CONCLUSIONS: This study showed
      that both LDL and LDLR are prognostic indexes for survival in patients with SCLC.
      Patients with high LDL or LDLR expression level may benefit from treatment that
      modulates lipoprotein combined with platinum-based chemotherapy.
FAU - Zhou, Ting
AU  - Zhou T
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Zhan, Jianhua
AU  - Zhan J
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Fang, Wenfeng
AU  - Fang W
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Zhao, Yuanyuan
AU  - Zhao Y
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Yang, Yunpeng
AU  - Yang Y
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Hou, Xue
AU  - Hou X
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Zhang, Zhonghan
AU  - Zhang Z
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - He, Xiaobo
AU  - He X
AD  - Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, 
      Zhuhai, 519000, People's Republic of China.
FAU - Zhang, Yaxiong
AU  - Zhang Y
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Huang, Yan
AU  - Huang Y
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China.
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651
      Dongfeng East Road, Guangzhou, 510060, People's Republic of China.
      [email protected]
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's
      Republic of China. [email protected]
AD  - Collaborative innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China. [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170414
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Receptors, LDL)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/biosynthesis/blood
MH  - Female
MH  - Humans
MH  - Lipoproteins, LDL/biosynthesis/*blood
MH  - Lung Neoplasms/*blood/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptors, LDL/blood
MH  - Retrospective Studies
MH  - Small Cell Lung Carcinoma/*blood/diagnosis
MH  - Young Adult
PMC - PMC5391547
OTO - NOTNLM
OT  - Low-density lipoprotein
OT  - Low-density lipoprotein receptor
OT  - Prognosis
OT  - Small-cell lung cancer
EDAT- 2017/04/16 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/16 06:00
PHST- 2016/09/09 [received]
PHST- 2017/03/28 [accepted]
AID - 10.1186/s12885-017-3239-z [doi]
AID - 10.1186/s12885-017-3239-z [pii]
PST - epublish
SO  - BMC Cancer. 2017 Apr 14;17(1):269. doi: 10.1186/s12885-017-3239-z.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>